Literature DB >> 3370019

Very low density lipoprotein triglyceride metabolism in relatives of hypertriglyceridemic probands. Evidence for genetic control of triglyceride removal.

T Sane1, E A Nikkilä.   

Abstract

The production and catabolism of very low density lipoprotein triglycerides (VLDL-TG) were determined in 11 index patients with primary hypertriglyceridemia and in their 70 first-degree relatives. In the probands the mean value for VLDL-TG production rate was twice normal, and the mean fractional catabolic rate (FCR) was reduced to 50% from normal. A similar kinetic pattern was also observed in most hypertriglyceridemic relatives. In the normotriglyceridemic relatives the mean values of both kinetic parameters were comparable to those of controls. No kinetic differences were observed between families with familial hypertriglyceridemia, familial combined hyperlipidemia, or genetically unclassified hypertriglyceridemia (all diagnosed by lipoprotein phenotypes). Thus, no explanation for the phenotypic differences between the two forms of familial hyperlipoproteinemia was found in plasma VLDL-TG metabolism. When the families were grouped according to the VLDL-TG production rate of the proband, there was no significant difference between the VLDL-TG production rates of relatives of "overproducer" probands and relatives of the probands with normal VLDL-TG production rate. In contrast, relatives of low FCR probands had significantly lower mean FCR than the relatives of probands with a normal FCR. This difference in FCR was present both in hypertriglyceridemic and normotriglyceridemic relatives. These results suggest that the catabolism (lipolysis) of VLDL-TG is under genetic control, whereas the VLDL-TG production rate is mainly related to obesity. It is likely that hypertriglyceridemia often develops on the basis of VLDL overproduction in individuals who have a genetically low VLDL triglyceride removal (lipolytic) capacity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3370019     DOI: 10.1161/01.atv.8.3.217

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  8 in total

1.  Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation.

Authors:  D E Wilson; M Emi; P H Iverius; A Hata; L L Wu; E Hillas; R R Williams; J M Lalouel
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

2.  Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.

Authors:  T Ebara; R Ramakrishnan; G Steiner; N S Shachter
Journal:  J Clin Invest       Date:  1997-06-01       Impact factor: 14.808

3.  Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.

Authors:  K Aalto-Setälä; E A Fisher; X Chen; T Chajek-Shaul; T Hayek; R Zechner; A Walsh; R Ramakrishnan; H N Ginsberg; J L Breslow
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

4.  Diagnostic value of post-heparin lipase testing in detecting common genetic variants in the LPL and LIPC genes.

Authors:  Mandy van Hoek; Geesje M Dallinga-Thie; Ewout W Steyerberg; Eric J G Sijbrands
Journal:  Eur J Hum Genet       Date:  2009-04-15       Impact factor: 4.246

5.  No evidence for linkage between familial hypertriglyceridemia and apolipoprotein B, apolipoprotein C-III or lipoprotein lipase genes.

Authors:  T Heliö; A Palotie; T Sane; M J Tikkanen; K Kontula
Journal:  Hum Genet       Date:  1994-09       Impact factor: 4.132

6.  Stable isotope-labeled tracers for the investigation of fatty acid and triglyceride metabolism in humans in vivo.

Authors:  Faidon Magkos; Bettina Mittendorfer
Journal:  Clin Lipidol       Date:  2009-04-01

7.  Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application.

Authors:  Scott Q Siler
Journal:  Pharm Res       Date:  2022-05-24       Impact factor: 4.580

8.  Triglycerides are a predictive factor for arterial stiffness: a community-based 4.8-year prospective study.

Authors:  Xiaona Wang; Ping Ye; Ruihua Cao; Xu Yang; Wenkai Xiao; Yun Zhang; Yongyi Bai; Hongmei Wu
Journal:  Lipids Health Dis       Date:  2016-05-18       Impact factor: 3.876

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.